<DOC>
	<DOCNO>NCT00427310</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give fluorouracil liver effective treatment patient colon cancer undergo surgery . PURPOSE : This randomized phase III trial study give infusion fluorouracil liver treat patient Dukes ' A , Dukes ' B , Dukes ' C colon cancer undergo surgery .</brief_summary>
	<brief_title>Liver Infusions Fluorouracil Treating Patients With Dukes ' A , Dukes ' B , Dukes ' C Colon Cancer Undergoing Surgery</brief_title>
	<detailed_description>OBJECTIVES : Determine whether adjuvant therapy portal hepatic perfusion 5-fluorouracil sodium heparin effectively prolong disease-free interval increase survival patient undergo curative resection adenocarcinoma colon . OUTLINE : Randomized study . Patients randomize preoperatively ; randomize Arm 1 begin therapy intraoperatively within 6 hour colonic resection . Arm 1 : 5-Fluorouracil plus sodium heparin . Those randomized Arm 2 receive adjuvant therapy . Arm 2 : observation ( treatment ) . PROJECTED ACCRUAL : 1,334 patient enter 4-year period .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>one synchronous primary colon tumor white blood cell ( WBC ) &gt; 4000/cu.mm . platelet count great equal 100,000/cu.mm . evidence adequate renal ( serum creatinine less equal 1.5 mg % ) hepatic function ( bilirubin less equal 1.5 mg % ; serum glutamic oxaloacetic transaminase ( SGOT ) less equal 60 I.U./ml ) performance status 0 , 1 2 Patients intestinal obstruction eligible . Preliminary complementary colostomy preclude entry patient provide randomization carry prior plan curative resection . The distal margin tumor must great equal 12 cm anal verge endoscopically measure patient kneechest position . Carcinoembryonic antigen ( CEA ) must perform preoperatively result need known time randomization . Exclusion criterion : malignant colon tumor carcinoma , i.e. , sarcoma , lymphoma , etc . patient whose tumor demonstrate free perforation previous concomitant malignancy , regardless site except patient squamous basal cell carcinoma skin , carcinoma situ cervix adequately treat patient receive prior treatment preliminary complementary colostomy ( radiation , chemotherapy surgery ) current malignancy . patient tumor within 12 cm anal verge performance status 3 4 patient nonmalignant systemic disease ( cardiovascular , renal , hepatic , etc . ) would preclude subject chemotherapy treatment option patient pregnant time randomization patient psychiatric addictive disorder would preclude obtain informed consent patient multiple primary tumor involve colon rectum would preclude classified colon cancer rectal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
</DOC>